Interlune announces deals for moon mining equipment — and for selling lunar helium-3
An artist's conception shows a rocket with a capsule containing helium-3 heading back to Earth from the moon's surface. (Interlune Illustration)
Seattle-based Interlune provided a triple-barreled update today on its progress toward mining helium-3 on the moon and returning that resource to Earth.
The startup joined Vermeer Corp., an industrial equipment manufacturer headquartered in Iowa, to unveil a full-scale prototype of an excavator that's designed to ingest 100 metric tons of moon dirt in an hour. After the helium-3 is extracted, the machine would drop the rest of the dirt back onto the lunar surface in a continuous motion.
Also today, Interlune announced separate agreements with the U.S. Department of Energy and Maybell Quantum Industries to start supplying lunar helium-3 by 2029.
Helium-3 is an isotope that's much rarer than the helium-4 that you typically find in lighter-than-air balloons. Helium-3 has a wide range of high-tech applications in fields that include quantum computing, fusion power, medical imaging and weapons detection for national security purposes.
The substance is hard to find on Earth, but it's more abundant on the moon due to bombardment by solar-wind particles. Interlune aims to take advantage of the potential market by extracting lunar helium-3 and shipping it back to Earth. The idea isn't exactly new; in fact, helium-3 mining was a key plot point in 'Moon,' a 2009 sci-fi movie. But Interlune is the first venture to try commercializing such an operation.
'The high-rate excavation needed to harvest helium-3 from the moon in large quantities has never been attempted before, let alone with high efficiency,' Gary Lai, Interlune co-founder and chief technology officer, said in a news release.
Lai served as chief architect for the New Shepard suborbital rocket ship built by Jeff Bezos' Blue Origin space venture, and went to space on New Shepard in 2022. That's not the only connection to Blue Origin: Interlune co-founder and CEO Rob Meyerson served as Blue Origin's president from 2003 to 2018.
Meyerson said Vermeer would be a key partner in the development of Interlune's harvesting system. 'When you're operating equipment on the moon, reliability and performance standards are at a new level,' he said. 'Vermeer has a legacy of innovation and excellence that started more than 75 years ago, which makes them the ideal partner for Interlune.'
Interlune and Vermeer tested a subscale version of the excavator last summer, setting the stage for the full-scale prototype unveiled today. Interlune said that the excavator is the first product resulting from the partnership, and that the companies will continue to explore other technologies for use in space and on Earth. For example, Interlune is working on methods for sorting, extracting and separating helium-3 from the dirt after it's excavated.
Vermeer CEO Jason Andringa will join Interlune's advisory board to deepen the partnership. 'Combining my personal passion for aeronautics and astronautics with Vermeer equipment that bears my grandfather's name, to carefully and responsibly harvest resources to make our world a better place, is something I'm incredibly proud of,' Andringa said.
Interlune and Vermeer worked together to test a full-scale prototype of an excavator with auxiliary components. The final version of the excavator hardware will be integrated into a machine known as the Interlune Harvester. (Interlune / Vermeer Photo)
An artist's conception shows the Interlune Harvester, which would incorporate excavation hardware that's currently being developed in partnership with Vermeer. (Interlune Illustration)
Interlune said Maybell Quantum would be the startup's first commercial customer. Under the terms of the purchase agreement, Interlune would provide thousands of liters of helium-3 for yearly delivery between 2029 and 2035. The helium-3 would be used in Maybell's dilution refrigerators, which cool quantum computing devices to near absolute zero.
'Helium-3 will fuel a fundamental transformation in computing,' Corban Tillemann-Dick, founder and CEO of Maybell Quantum, said in a news release. 'In the coming years, we'll go from a few hundred quantum computers worldwide to thousands, then tens of thousands, and they all need to get cold. To get cold, they need dilution refrigeration running on helium-3.'
Interlune also said it planned to deliver three liters of lunar helium-3 to the U.S. Department of Energy by April 2029. Under the terms of that agreement, the helium-3 would be purchased 'at approximately today's commercial market price,' the company said in a news release.
Interlune has pegged the commercial price of helium-3 at $20 million per kilogram. The price per liter would be significantly lower, however. Last year, a market report from the Edelgas Group said helium-3 was trading at around $2,500 per liter.
The agreement with the Department of Energy marks the first purchase of a non-terrestrial natural resource under the terms of the DOE Isotope Program, Interlune said. 'With this agreement, the DOE IP is signaling to companies and investors that it supports novel approaches to securing critical materials for use on Earth, including space resources,' Meyerson said.
Last year, Interlune received a grant from the DOE Isotope Program to study a low-temperature method for separating helium-3 from domestic helium supplies, in partnership with Pacific Northwest National Laboratory. The company plans to leverage findings from that project to support its plans for lunar helium-3 extraction.
Interlune, which was founded in 2020, has also received grants from NASA and the National Science Foundation to work on technologies for processing lunar soil. Last year, the company said it raised $18 million in seed funding. And last month, it won a grant of up to $4.84 million from the Texas Space Commission to open a center focusing on the processing of simulated moon dirt.
In a video posted to LinkedIn, Nina Hooper, Interlune's director of business development, laid out the company's roadmap for testing its hardware on the moon.
The plan calls for executing three missions over the next five years. 'Our first mission, Crescent Moon, is coming up at the end of this year, 2025,' Hooper said. 'We'll be sending a hyperspectral camera as a rideshare to the south pole with another lunar mission.'
That mission would be followed by Prospect Moon. 'We'll be taking a lander to an area of our choosing where we believe the helium-3 concentration is highest,' Hooper said. 'We'll be taking an advanced suite of sensors and some technology demonstrations to validate the concentration of helium-3 and prove out our method of extracting it.'
Hooper said the third mission, Harvest Moon, would be an end-to-end demonstration of the process for extracting helium-3 and sending it back to Earth. The timing for that mission may have some connection to plans for delivering helium-3 to the Department of Energy.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts
These biotech companies have several catalysts ahead -- and in the past have soared on good news. They both offer innovative candidates that could result in game-changing treatments for patients. 10 stocks we like better than Viking Therapeutics › If you're looking to add growth to your portfolio, biotech stocks can be a great choice. Exciting research is happening in these companies' labs, and in some cases, game-changing treatment candidates are approaching important milestones or even going over the finish line. As an investor in these companies, you can benefit as they report positive clinical trial news, score a regulatory approval, or start generating product revenue. Wall Street considers two candidates extremely compelling right now, with forecasts for potential gains of more than 80% and 200% in the coming 12 months. One of these players is working in the high-growth area of weight loss drugs, and the other candidate showed its strengths by winning the world's first-ever approval of a product based on CRISPR gene editing. Let's check out these two biotech stocks to buy before they skyrocket. Viking Therapeutics (NASDAQ: VKTX) soared early last year when it reported strong data from the phase 2 trial of its weight loss candidate, VK2735, but the stock has since given back those gains and is trading closer to the level it was at prior to that data announcement. Since, the company has continued to advance VK2735 in injectable form and a version in pill form, and demand for these sorts of drugs remains high -- these are two reasons to believe that Viking has the potential to take off again. And catalysts may be on the horizon. The drug works in a manner similar to Eli Lilly's blockbuster tirzepatide, sold under the names Mounjaro and Zepbound. These drugs interact with hormones involved in digestion and have helped people quickly and safely lose weight. Viking is beginning the phase 3 trial for injectable VK2735 in the second quarter and expects data from its phase 2 trial of the pill version in the second half. Any data announcements could result in big moves for the stock, as there is plenty of room for a new company to enter the weight loss drug market -- one forecast to approach $100 billion in a few years. Wall Street is optimistic about Viking's prospects, with the average price forecast predicting an increase of about 240% in the stock price from today's level. Of course, Viking depends heavily on the outcome of these trials, so some risk is involved -- but data have been strong, so growth investors may want to get in on Viking now to potentially post a big win later. CRISPR Therapeutics (NASDAQ: CRSP) stock surged in the year leading up to a major milestone: its first product approval. But since last year's launch of Casgevy, a gene-editing treatment for blood disorders, the stock has been on the decline. Sometimes, investors buy a stock well before the company wins approval or launches a product, then lock in gains after the good news lands -- and I think this is what's happened here. But what this does is offer us a chance to get in at a very good price on a promising company that could deliver fantastic news down the road. Casgevy, as a gene-editing treatment, requires a longer time to roll out than a pill or injection, as it includes several steps that happen over a period of months. The company recently said new patient initiations should increase "significantly" this year -- so there's reason to be optimistic about revenue growth ahead. CRISPR Therapeutics also recently reported positive phase 1 data for a gene editing candidate addressing the problem of high cholesterol. And the company expects to report data soon from a phase 1 trial of a candidate targeting patients with elevated levels of lipoprotein(a) -- a risk factor for cardiovascular events. These could represent huge markets for CRISPR Therapeutics if the candidates reach the finish line, and in the meantime, any potential positive news could boost the stock. The company also expects other trial updates in candidates for oncology and autoimmune diseases this year -- so this biotech's calendar is full of possible catalysts. Wall Street's average price forecast calls for an 84% gain for CRISPR Therapeutics from today's price -- if all goes well in clinical trials and Casgevy starts to show revenue growth, now could represent a golden buying opportunity for growth investors. Before you buy stock in Viking Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Viking Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $664,089!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $881,731!* Now, it's worth noting Stock Advisor's total average return is 994% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends CRISPR Therapeutics. The Motley Fool recommends Viking Therapeutics. The Motley Fool has a disclosure policy. 2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24 minutes ago
- Yahoo
Dan Ives Says Market Is 'Massively Underestimating' This AI Play, Urges Investors To Look Beyong Mag 7
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Dan Ives' new artificial intelligence exchange-traded fund (ETF) holds securities beyond the Magnificent 7 stocks, as he believes in looking past valuations for investments in the technology sector. What Happened: The Dan IVES Wedbush AI Revolution ETF (NYSE:IVES), managed by the Wedbush analyst, started trading on June 4, earlier this month. Ives boasts of the fund by saying that it just doesn't have the top four, five Magnificent 7 names, but stocks which investors wouldn't even thematically consider as an AI name today. "I believe the market is still massively underestimating what the growth is going to look like for the AI revolution in tech," he told CNBC. Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — According to him, tech trade remains significant even for the investors who missed out on its growth in the past few years. "If you focus just on valuation, you miss every transformational tech stock of the last 20 years," Ives said. Ives says Oracle Corp. (NYSE:ORCL) will be the 'epicenter' of the AI theme, while highlighting other 'AI 30' stocks which are part of his fund. Palantir Technologies Inc. (NASDAQ:PLTR), International Business Machines Corp. (NYSE:IBM), Salesforce Inc. (NYSE:CRM), SoundHound AI Inc. (NASDAQ:SOUN), and Innodata Inc. (NASDAQ:INOD) are a few notable names that are a part of his ETF's 'AI 30' basket. Microsoft Corp. (NASDAQ:MSFT), Nvidia Corp. (NASDAQ:NVDA), and Broadcom Inc. (NASDAQ:AVGO) are the top three holdings of the IVES It Matters: The 'AI 30' stocks, which are a part of the IVES ETF, hold the AI plays from multiple industries. They include hyperscalers, cybersecurity, consumer platforms, and robotics. According to Ives, the list was compiled from his deep dives into major AI players. The ETF has $183 million in assets under management as of June 17 close. Ives said that the AI space was experiencing a "golden age." The Dan IVES Wedbush AI Revolution ETF has risen by 2.76% since its inception. A comparable index, S&P Kensho Global Artificial Intelligence Enablers, rose 6.08% on a month-to-date basis. Meanwhile, the SPDR S&P 500 ETF Trust (NYSE:SPY) and Invesco QQQ Trust ETF (NASDAQ:QQQ), which track the S&P 500 index and Nasdaq 100 index, respectively, declined slightly on Wednesday. The SPY was down 0.015% at $597.44, while the QQQ was 0.017% lower at $528.99, according to Benzinga Pro data. Read Next: Invest early in CancerVax's breakthrough tech aiming to disrupt a $231B market. Back a bold new approach to cancer treatment with high-growth potential. If there was a new fund backed by Jeff Bezos offering a 7-9% target yield with monthly dividends would you invest in it? Photo courtesy: Shutterstock This article Dan Ives Says Market Is 'Massively Underestimating' This AI Play, Urges Investors To Look Beyong Mag 7 originally appeared on
Forbes
25 minutes ago
- Forbes
Google's Quiet Confirmation Of The Pixel 10
Google's "Talking Phones Podcast" title card Google is having a little bit of fun in its latest iPhone vs Pixel video. While the Pixel 9 Pro takes pride of place, there's also a surprising cameo for what comes next… the Pixel 10. The Pixel 10 Easter Egg The details come at the end of Google's latest promotional video posted on its Made By Google YouTube channel. In it, an iPhone and a Pixel talk about the recent advances made by Apple's smartphone, with a not at all surprised Pixel noting when that feature arrived on Pixel and Android. These include live translation, hold assistance and call screening arriving four, five and seven years ago respectively., Of course, the capabilities of all these features have improved significantly over the last few years, so there are shades of Oranges to (ahem) Apples here, but it makes Google's point effectively. The story of Android being ahead of iOS is here for all to hear. The little easter egg at the end is part of another story, leading into the next Pixel release. The iPhone quietly asks the Pixel 9 Pro, 'so, what are you working on for Pixel 10… just out of curiosity?' Naming The Pixel 10 It's no secret that Google is working on the next family of Pixel smartphones. Neither is it a secret that we're expecting an entry-level Pixel 10, a premium Pixel 10 Pro, a larger Pixel 10 Pro XL and an innovative Pixel 10 Pro Fold. Yet this is the first time Google has publicly acknowledged that the new handsets will carry the Pixel 10 branding. Although the sharp-eared watchers will note that it was the iPhone confirming the new Pixel 10, not the Pixel 9 Pro. So, did Apple confirm the new name, rather than Google? Google is expected to announce the Pixel 10 family at an upcoming Made By Google event. While dates have not been confirmed, talk within the community picks out Wednesday, Aug. 20 for the launch, and Thursday, Aug 28. for the first handsets to go on sale to the public. Now read how the Pixel 10 will impact every Android smartphone in 2025 and beyond…
